medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2015, Número 2

<< Anterior Siguiente >>

Rev Med UV 2015; 15 (2)


Laxantes con fenolftaleína y su relación con el desarrollo de cáncer

Herrera-Covarrubias D, Fernández-Pomares C, Coria-Ávila GA, Manzo DJ, Aranda-Abreu GE, Hernández AME

Idioma: Español
Referencias bibliográficas: 56
Paginas: 91-101
Archivo PDF: 404.38 Kb.


RESUMEN

Los laxantes son sustancias utilizadas para provocar la defecación, ya sea por estimulación química de la motilidad intestinal o por un efecto de lubricación de las heces, por lo que suelen ser prescritos para tratar el estreñimiento. La fenolftaleína es un laxante cuyo abuso ha sido asociado en algunos estudios con parálisis intestinal, perturbaciones electrolíticas, hemorroides, pérdida de la función intestinal, pancreatitis y el desarrollo de diversos tipos de cáncer. En esta revisión se reporta literatura científica relacionada con el abuso prolongado de laxantes que contienen fenolftaleína y su relación en el desarrollo de cáncer. Los resultados de nuestra búsqueda bibliográfica sugieren que el abuso prolongado de laxantes a base de fenolftaleína debería considerarse un factor de riesgo en el desarrollo del cáncer. Dicha evidencia es más clara en modelos animales e in vitro que en humanos. Por lo tanto, se requiere de más estudios para determinar su mecanismo carcinogénico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. OMS. Cáncer. Datos y cifras. Nota descriptiva N.297. 2015; Disponible en: http://www.who.int/ mediacentre/factsheets/fs297/es/.

  2. Williams TH. Occult carcinoma and benign hypertrophy of the prostate in men over fifty years of age. Treat Serv Bull 1954; 9:201-16.

  3. Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK, et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiation therapy. Cancer Epidemiol Biomarkers Prev 2014.

  4. Chang SN, Han J, Abdelkader TS, Kim TH, Lee JM, Song J, et al. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice. Prostate 2014; 74:1266-77.

  5. Haque R, Van Den Eeden SK, Wallner LP, Richert-Boe K, Kallakury B, Wang R, et al. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract 2014; 8:e374-81.Roman MD, Niclis C, Tumas N, Diaz Mdel P, Osella AR, Munoz SE. Tobacco smoking patterns and differential food effects on prostate and breast cancers among smokers and nonsmokers in Cordoba, Argentina. Eur J Cancer Prev 2014; 23:310-8.

  6. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.

  7. Rao A, Agarwal S. Role of lycopene as antioxidante carotenoid in the prevention of chronic diseases: a review. Nutrition research 1999; 19:305-323.

  8. Johnson IT. Understanding the association between diet and nutrition in upper gastrointestinal cancer. Expert Rev Gastroenterol Hepatol 2015; 1-3.

  9. Liu P, Holman CD, Jin J, Zhang M. Diet and risk of adult leukemia: a multicenter case-control study in China. Cancer Causes Control 2015;26:1141-51.

  10. Mourouti N, Kontogianni MD, Papavagelis C, Plytzanopoulou P, Vassilakou T, Psaltopoulou T, et al. Meat consumption and breast cancer: a case-control study in women. Meat Sci 2015;100:195- 201.

  11. OMS. Apartado. Temas de salud, Cáncer. 2014;Disponible en: http://www.who.int/topics/cancer/ es/.

  12. National Toxicology P. Phenolphthalein. Rep Carcinog 2011; 12:342-4.

  13. Tierney L, McPhee S, Papadakis M, Diagnóstico clínico y tratamiento. 2000, Manual Moderno. p. 535-636.

  14. Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol 2003;36:386-9.

  15. Lambrianides AL, Rosin RD. Acute pancreatitis complicating excessive intake of phenolphthalein. Postgrad Med J 1984;60:491-2.

  16. Izzo AA, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci 1998; 43:1605-20.

  17. Powell DW, Johnson PT, Bryson JC, Orlando RC, Fan CC. Effect of phenolphthalein on monkey intestinal water and electrolyte transport. Am J Physiol 1982;243:G268-75.

  18. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Phenolphthalein laxatives and risk of cancer. J Natl Cancer Inst 2000; 92:1943-4.

  19. National Toxicology P. NTP Toxicology and Carcinogenesis Studies of Phenolphthalein (CAS No. 77-09-8) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1996;465:1-354.

  20. Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, et al. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Toxicol Pathol 1997; 25:533-40.

  21. Dunnick JK, Hailey JR. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 1996; 56:4922-6.

  22. Imaoka M, Kashida Y, Watanabe T, Ueda M, Onodera H, Hirose M, et al. Tumor promoting effect of phenolphthalein on development of lung tumors induced by N-ethyl-N-nitrosourea in transgenic mice carrying human prototype c-Ha-ras gene. J Vet Med Sci 2002;64:489-93.

  23. Ravdin PM, van Beurden M, Jordan VC. Estrogenic effects of phenolphthalein on human breast cancer cells in vitro. Breast Cancer Res Treat 1987; 9:151-4.

  24. Tsutsui T, Tamura Y, Yagi E, Hasegawa K, Tanaka Y, Uehama A, et al. Cell-transforming activity and genotoxicity of phenolphthalein in cultured Syrian hamster embryo cells. Int J Cancer 1997; 73:697-701.

  25. Koujitani T, Yasuhara K, Usui T, Nomura T, Onodera H, Takagi H, et al. Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study. Cancer Lett 2000; 152:211-6.

  26. French JE, Lacks GD, Trempus C, Dunnick JK, Foley J, Mahler J, et al. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis 2001; 22:99-106.

  27. Sipe HJ, Jr., Corbett JT, Mason RP. In vitro free radical metabolism of phenolphthalein by peroxidases. Drug Metab Dispos 1997;25:468-80.

  28. Herrera-Covarrubias D, Fernández Pomares C, Aranda Abreu G, Dominguez Ortíz M, Hernández Aguilar M. The role of lycopene in prevention of prostate cancer. Revista eNeurobiología 2013;4:1-16.

  29. Vitale A, Bernatene E, Pomillo A. Carotenoids in chemoprevention: Lycopene. Acta Bioquím Clín Latinoam 2010; 44:195-238.

  30. Feng M, Feng C, Yu Z, Fu Q, Ma Z, Wang F, et al. Histopathological alterations during breast carcinogenesis in a rat model induced by 7,12-Dimethylbenz (a) anthracene and estrogen-progestogen combinations. Int J Clin Exp Med 2015; 8:346-57.

  31. Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. Z Gastroenterol 1993; 31:140-3.

  32. Longnecker MP, Sandler DP, Haile RW, Sandler RS. Phenolphthalein-containing laxative use in relation to adenomatous colorectal polyps in three studies. Environ Health Perspect 1997;105:1210-2.

  33. Jacobs EJ, White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998;9:385-91.

  34. Tice RR, Furedi-Machacek M, Satterfield D, Udumudi A, Vasquez M, Dunnick JK. Measurement of micronucleated erythrocytes and DNA damage during chronic ingestion of phenolphthalein in transgenic female mice heterozygous for the p53 gene. Environ Mol Mutagen 1998;31:113-24.

  35. Cooper GS, Longnecker MP, Sandler DP, Ness RB. Risk of ovarian cancer in relation to use of phenolphthalein-containing laxatives. Br J Cancer 2000; 83:404-6.

  36. Cooper GS, Longnecker MP, Peters RK. Ovarian cancer risk and use of phenolphthalein-containing laxatives. Pharmacoepidemiol Drug Saf 2004; 13:35-9.

  37. Banhidy F, Acs N, Puho EH, Czeizel AE. Phenolphthalein treatment in pregnant women and congenital abnormalities in their offspring: A population-based case-control study. Drug Discov Ther 2008;2:357-67.

  38. Heard PL, Rubitski EE, Spellman RA, Schuler MJ. Phenolphthalein induces centrosome amplification and tubulin depolymerization in vitro. Environ Mol Mutagen 2013; 54:308-16.

  39. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 2009;66:2405-26.

  40. Noriega-Reyes M, Langley McCarron E. Correguladores del Receptor de Estrógenos y su Implicación en el Cáncer Mamario. Cancerología 2008;3:29-40.

  41. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61:2537-41.

  42. Finlay-Schultz J, Sartorius CA. Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia 2015;20:39-50.

  43. Locia Espinoza J, Hernández Aguilar M, Aranda Abreu G, Rojas Durán F, Manzo Denes J, Coria Ávila G, et al. The role of estrogens and their receptors in prevention and promotion of proliferative diseases in the prostatic gland. eNeurobiología 2013;4:1-23.

  44. Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem 2010; 53:3273-83.

  45. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005;23:1644-55.

  46. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: a look ahead. Drugs 1999; 57:653-63.

  47. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997; 57:2606-10.

  48. Huynh HT, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 1993;53:5585-8.

  49. Candanedo-González F, Pérez-Salazar E. The role of progesterone in breast cancer. Gaceta Mexicana de Oncología (GAMO) 2012;11.Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond Engl) 2008; 4:151-62.

  50. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395-403.

  51. Sukumar S, Notario V, Martin-Zanca D, Barbacid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 1983; 306:658-61.

  52. Armstrong MJ, Gara JP, Gealy R, 3rd, Greenwood SK, Hilliard CA, Laws GM, et al. Induction of chromosome aberrations in vitro by phenolphthalein: mechanistic studies. Mutat Res 2000;457:15-30.

  53. Fenech M, Holland N, Chang WP, Zeiger E, Bonassi S. The HUman MicroNucleus Project--An international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res 1999; 428:271-83.

  54. Bolognesi C, Bruzzi P, Gismondi V, Volpi S, Viassolo V, Pedemonte S, et al. Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility. PLoS One 2014;9:e112354.

  55. Dietz DD, Elwell MR, Chapin RE, Shelby MD, Thompson MB, Filler R, et al. Subchronic (13- week) toxicity studies of oral phenolphthalein in Fischer 344 rats and B6C3F1 mice. Fundam Appl Toxicol 1992;18:48-58.

  56. Holden HE. Phenolphthalein: a sheep in wolf’s clothing? Environ Mol Mutagen 1998;31:103-4.




2020     |     www.medigraphic.com